Clinical Trial

Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-26.
Trial Details
NCT Number NCT05847179
Lead Sponsor PRG Science & Technology Co., Ltd.
Conditions Werner Syndrome
Enrollment 5 participants
Start Date 2026-07
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-23